Argitalpenak (45) GUILLERMO OVIDIO VILLA VALDES argitalpenak

2024

  1. A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels

    Upsala journal of medical sciences, Vol. 129

2023

  1. European Physician Survey Characterizing the Clinical Pathway and Treatment Patterns of Patients Post-Myocardial Infarction

    Advances in Therapy, Vol. 40, Núm. 1, pp. 233-251

  2. Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI

    Cardiovascular Drugs and Therapy, Vol. 37, Núm. 5, pp. 941-953

  3. Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study

    The Lancet Regional Health - Europe, Vol. 31

2022

  1. Achieving Lower LDL-C Levels After a Recent Myocardial Infarction Might Be Associated with Lower Healthcare Resource Use and Costs in Spain

    Advances in Therapy, Vol. 39, Núm. 8, pp. 3578-3588

  2. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 8, Núm. 1, pp. 31-38

  3. Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study

    Upsala Journal of Medical Sciences, Vol. 127

  4. Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK

    BMJ open, Vol. 12, Núm. 4, pp. e055015

  5. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 8, Núm. 4, pp. 447-460

  6. Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol

    Journal of the American Heart Association, Vol. 11, Núm. 18

2021

  1. Cardiovascular Event Rates After Myocardial Infarction or Ischaemic Stroke in Patients with Additional Risk Factors: A Retrospective Population-Based Cohort Study

    Advances in Therapy, Vol. 38, Núm. 9, pp. 4695-4708

  2. Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients

    International Journal of Cardiology, Vol. 332, pp. 22-28

  3. Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom

    European Journal of Preventive Cardiology, Vol. 28, Núm. 3, pp. 335-343

  4. Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease

    Clinical Cardiology, Vol. 44, Núm. 10, pp. 1457-1466

  5. Screening and treatment of familial hypercholesterolemia in a French sample of ambulatory care patients: A retrospective longitudinal cohort study

    PLoS ONE, Vol. 16, Núm. 8 August

2020

  1. Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: A systematic literature review

    Health and Quality of Life Outcomes, Vol. 18, Núm. 1

2019

  1. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: Estimates from Swedish population-based register data

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 5, Núm. 3, pp. 225-232

  2. Comparison of Recommendations and Use of Cardiovascular Risk Equations by Health Technology Assessment Agencies and Clinical Guidelines

    Value in Health, Vol. 22, Núm. 2, pp. 210-219

  3. Costs of Acute Headache Medication Use and Productivity Losses Among Patients with Migraine: Insights from Three Randomized Controlled Trials

    PharmacoEconomics - Open, Vol. 3, Núm. 3, pp. 411-417

  4. Longitudinal assessment of utilities in patients with migraine: An analysis of erenumab randomized controlled trials

    Health and Quality of Life Outcomes, Vol. 17, Núm. 1